• First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.
  • Strategic Account: This new lab's scale and geographic reach across Europe positions it as a reference account and potential gateway to broader EU laboratory channel adoption.
  • Repeat Order Potential: Based on the nature of the relationship, Biomerica believes this initial order will result in recurring orders as Hp Detect™ is integrated into the customer's routine testing workflow.
  • Disease Burden: H. pylori affects an estimated 45% of the population across Europe's five largest countries. The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest threat to human health globally.

IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.